Vimarsana
Biggest News Aggregation in the World

Sustained Benefit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sustained Benefit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sustained Benefit Today - Breaking & Trending Today

Patient on Esketamine had Improved Depression, Fibromyalgia - Vimarsana News

Patient on Esketamine had Improved Depression, Fibromyalgia

Treatment-resistant depression with intranasal esketamine was linked to improvements in major depressive disorder (MDD) symptoms and fibromyalgia pain in a 40-year-old female.

Psilocybin and Psychotherapy Can Improve Depression in Patients With Cancer - Vimarsana News

Psilocybin and Psychotherapy Can Improve Depression in Patients With Cancer

Psilocybin and psychotherapy sessions provided a sustained improvement in depressive symptoms in patients with cancer. Psilocybin, when used in combination with psychotherapy sessions, may reduce or eliminate depression in patients with cancer.

Source: empr.com
Psilocybin and Psychotherapy Can Improve Depression in Patients With Cancer - Vimarsana News

Psilocybin and Psychotherapy Can Improve Depression in Patients With Cancer

Psilocybin and psychotherapy sessions provided a sustained improvement in depressive symptoms in patients with cancer. Psilocybin, when used in combination with psychotherapy sessions, may reduce or eliminate depression in patients with cancer.

AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society Annual Scientific Meeting - Vimarsana News

AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society Annual Scientific Meeting

ABBVie today announced data from its migraine portfolio will be presented at the 2021 American Headache Society Annual Scientific Meeting, to be held virtually June 3-6 . A total of 23 abstracts, including four podium presentations, will be shared from a broad range of studies across ABBVie's migraine portfolio. "Migraine is an often-debilitating disease that affects millions of people in the prime of their lives, ...